BioIVT is sourcing matched sets of cerebrospinal fluid, serum, and plasma from donors afflicted with ALS to further research of neurofilament in the blood as a biomarker for early stages of neurodegeneration.
Discovery Park, the Life Sciences Opportunity Zone for ambitious and growing life sciences companies, has launched its investment fund, Discovery Park Ventures (DPV), with stakes in VisusNano and Vitarka Therapeutics.
Exploristics is delighted to announce the launch of the latest release of our revolutionary clinical trial simulation software, KerusCloud Spring 2022. An innovative platform that provides powerful state-of-the-art cloud-based study simulation capabilities to clinical developers of all sizes, KerusCloud tackles the complex challenges involved in designing effective clinical trials.
In light of Deaf Awareness Week, we interviewed Simon Chandler, Chief-Executive of Rinri Therapeutics, a preclinical stage biotechnology company focused on developing advanced regenerative cell therapies for hearing loss.
The company’s lead therapeutic candidate, Rincell-1, receives innovative medicine designation under new programme designed to accelerate the drug approval process and improve patient access in the United Kingdom.
Rinri appoints Professor Doug Hartley as Chief Medical Officer, and Sheila Casserly as Director of Clinical Operations, to lead the company’s clinical development strategy to support the continued advancement of Rincell-1 towards first-in-human trials.
Cancer Research UK, the world’s largest independent funder of cancer research, today (Tuesday 26th), unveiled Cancer Research Horizons, its new and ambitious approach to driving innovation in the development of new treatments for patients, by combining the power of academia and industry.
Two new antimicrobial drugs - cefiderocol and ceftazidime–avibactam - are close to becoming the first to be made available as part of the UK’s innovative subscription-style payment model after NICE today (Tuesday, 12 April 2022) published draft guidance estimating their value to the NHS.